Indication

Blood transfusion related iron overload in patients with myelodysplastic syndrome

RAG rating

Double Red

Document type

Decision document

Place

Hertfordshire and West Essex ICB

Output type

Pharmacy / Prescribing

Iron chelators

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)

 Iron chelators for blood transfusion related iron overload in patients with myelodysplastic syndrome

 DOUBLE RED

Not recommended for primary or secondary care prescribing 

Name generic (trade) Desferrioxamine, deferiprone, deferasirox

What it is Iron chelator

Indication Blood transfusion related iron overload in patients with myelodysplastic syndrome

Date decision last revised September 2017

Decision status Final

NICE / SMC Guidance NICE - No guidance SMC - Recommended (deferasirox)

HWE APC recommendation

To ratify the East of England Priority Advisory Committee (PAC) recommendations that iron chelators are not routinely commissioned for the treatment of blood transfusion related iron overload in patients with myelodysplastic syndrome within Hertfordshire.

Please note: NHS England is the responsible commissioner for iron chelation in thalassaemia and sickle cell. 

Review date: The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available